A Phase II Trial Of ZD1839 (Iressa) In Metastatic Neuroendocrine Tumors

Trial Profile

A Phase II Trial Of ZD1839 (Iressa) In Metastatic Neuroendocrine Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2011 Status changed from active, no longer recruiting to completed.
    • 19 Jul 2007 Status change
    • 04 Jun 2007 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top